The pharmacokinetics of lurasidone in pediatric patients aged 6-17 years were generally similar to those observed in adults.
No information is present at this moment.
No information is present at this moment.
| Schizophrenia |
|---|
|
Adjustment in renal impairment as specified:
In renal impairment, lurasidone exposure is increased. This increases the risk of side effects.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Very common (> 10%): akathisia, headache, somnolence. Nausea.
Common (1-10%): hyperprolactinaemia. Decreased or increased appetite. Abnormal dreams, agitation, anxiety, depression, insomnia, psychotic disorder, schizophrenia, tension. Attention disorder, dizziness, dyskinesia, dystonia, parkinsonism. Tachycardia. Dry mouth, salivation, vomiting, constipation. Hyperhidrosis. muscle stiffness. erectile dysfunction. Fatigue, asthenia, irritation. Increase in CK, increase in C-reactive protein. weight change.
Uncommon (0.1-1%): nasopharyngitis, rhinitis, upper respiratory tract infection. Neutropenia. Hypersensitivity. Autoimmune thyroiditis, hypothyroidism, hyperandrogenism. Aggression, apathy, confusion, depressed mood, dissociation, auditory and visual hallucinations, homicidal ideation, mental status change, mental disorder, impulsive behavior, sleep disturbance, libido decreased or increased, listlessness, obsessive thoughts, panic attack, restlessness, sleep disorder, suicidal ideation and behaviour, poor sleep, abnormal thinking. Postural dizziness, tension headache, dysgeusia, memory impairment, migraine, paresthesia, psychomotor hyperactivity, hyperkinesia, tardive dyskinesia, restless legs syndrome, gait disorder. Accommodation disorder, blurred vision. hyperacusis. Palpitations, supraventricular extrasystoles. Orthostatic hypotension. Oropharyngeal pain. Dyspnea. Dry lips, toothache, decreased salivation, dyspepsia, (upper) abdominal pain, diarrhoea. Skin rash, urticaria, alopecia, abnormal hair growth. Arthralgia, myalgia, muscle tension, stiff muscles and joints, pain in extremity, jaw pain. Bilirubinuria, dysuria, micturition disorder, polyuria, proteinuria, renal disorder. Amenorrhea, oligomenorrhea, menstrual irregularities, breast pain, galactorrhea, gynecomastia, ejaculation disorder, sexual dysfunction. Gilles de la Tourette syndrome. Chills, fever, non-cardiac chest pain, malaise. ALT and AST increase, AF increase or decrease, cholesterol and triglycerides increase, HDL and LDL decrease, testosterone increase, blood glucose increase, blood insulin increase, TSH increase, hemoglobin decrease, thyroid positive antibodies, shortened PR-interval on ECG.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific warnings and precautions in children.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Phenothiazines with aliphatic side-chain | ||
|---|---|---|
| N05AA02 | ||
| Butyrophenone derivatives | ||
|---|---|---|
| N05AD01 | ||
| N05AD05 | ||
| Indole derivatives | ||
|---|---|---|
| N05AE04 | ||
| Diphenylbutylpiperidine derivatives | ||
|---|---|---|
| N05AG02 | ||
| Diazepines, oxazepines, thiazepines and oxepines | ||
|---|---|---|
| N05AH02 | ||
| N05AH03 | ||
| N05AH04 | ||
| Lithium | ||
|---|---|---|
| N05AN01 | ||
| Other antipsychotics | ||
|---|---|---|
| N05AX12 | ||
| N05AX13 | ||
| N05AX08 | ||